Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bemcentinib + Erlotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bemcentinib||BGB-324|BGB324|R428|R-428||AXL Inhibitor 27||Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766).|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 47 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (FDA.gov; PMID: 25302162).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02424617||Phase Ib/II||Bemcentinib + Erlotinib||A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer||Unknown status|